Development asset linked to PharmaEssentia in public FDA and regional records.
pharma · Polycythemia Vera (PV) · Primary Myelofibrosis
PharmaEssentia
PharmaEssentia drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Burlington, USA HQ
2003 Founded
356 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Burlington, USA
- Founded
- 2003
- Employees
- 356
- Programs
- 2
- Drugs
- 3
- Patents
- 0
PharmaEssentia pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PharmaEssentia drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to PharmaEssentia in public FDA and regional records.
-
ropeginterferon alfa-2b
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in PharmaEssentia's portfolio. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor positive modulator